Adjuvant Avelumab in Merkel Cell Cancer

This randomized phase III trial studies how well avelumab works in treating patients with Merkel cell cancer that has spread to the lymph nodes and have undergone surgery and/or radiation therapy. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

NCT Number	NCT03271372
Lead Sponsor	University of Washington Collaborators: EMD Serono
Conditions	Stage III Merkel Cell Carcinoma AJCC v8, Stage IIIB Merkel Cell Carcinoma AJCC v8, Stage IIIA Merkel Cell Carcinoma AJCC v8
Enrollment	101 participants
Start Date	2017-12-19
Primary Completion	2029-01-31 (estimated)
Study Completion	2029-02-18 (estimated)
Updated on ClinicalTrials.gov	2026-06-15